Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro

Cancer Gene Therapy volume 24, pages 289–296 (2017)Cite this article

Subjects

Abstract

Recently, the US FDA approved sipuleucel-T, which is composed of autologous DCs stimulated with a recombinant fusion protein of prostatic acid phosphatase (PAP) and granulocyte-macrophage colony-stimulating factor (GM-CSF), as the first immunotherapeutic agent for metastatic castration resistant prostate cancer (mCRPC). However, sipuleucel-T demonstrated only modest efficacy in mCPRC patients. Researchers are now investigating the potential of p53 protein as a tumor-associated antigen (TAA) loaded in DC-based cancer vaccine. Approximately half of all tumors overexpress p53, and up to 20% of prostate cancer cells overexpresses p53. In this study, we evaluated the feasibility of combining p53-DC vaccine and rAd-p53 gene therapy, using the p53-overexpressing and non-expressing prostate cancer cells in vitro. We successfully generated the p53-DC vaccine by culturing autologous DCs infected with rAd-p53. This p53-DC vaccine can differentiate CTLs specifically cytotoxic to p53-overexpressing prostate cancer cells. In addition, rAd-p53 infection can induce overexpression of p53 and thus the cytotoxicity of CTLs differentiated by the p53-DC vaccine in p53 non-expressing prostate cancer cells. These findings suggest that this combination therapy using p53-DC vaccine and rAd-p53 gene therapy together may represent a new paradigm for the treatment of mCRPC.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Zou W . Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005; 5: 263–274.

    Article  CAS  Google Scholar 

  2. Khong HT, Restifo NP . Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol 2002; 3: 999–1005.

    Article  CAS  Google Scholar 

  3. Bilgin B, Sendur MA, Bülent Akıncı M, Şener Dede D, Yalçın B . Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. Curr Med Res Opin 2017; 31: 1–11.

    Google Scholar 

  4. Ilie M, Hofman V, Dietel M, Soria JC, Hofman P . Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients. Virchows Arch 2016; 468: 511–525.

    Article  CAS  Google Scholar 

  5. O'Donnell JS, Smyth MJ, Teng MW . Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade? Genome Med 2016; 8: 111.

    Article  Google Scholar 

  6. O'Donnell JS, Long GV, Scolyer RA, Teng MW, Smyth MJ . Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev 2017; 52: 71–81.

    Article  CAS  Google Scholar 

  7. Sawada Y, Yoshikawa T, Shimomura M, Iwama T, Endo I, Nakatsura T . Programmed death-1 blockade enhances the antitumor effects of peptide vaccine-induced peptide-specific cytotoxic T lymphocytes. Int J Oncol 2015; 46: 28–36.

    Article  CAS  Google Scholar 

  8. Reyes D, Salazar L, Espinoza E, Pereda C, Castellón E, Valdevenito R et al. Tumour cell lysate-loaded dendritic cell vaccine induces biochemical and memory immune response in castration-resistant prostate cancer patients. Br J Cancer 2013; 109: 1488–1497.

    Article  CAS  Google Scholar 

  9. Lee JH, Lee Y, Lee M, Heo MK, Song JS, Kim KH et al. A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Br J Cancer 2015; 113: 1666–1676.

    Article  CAS  Google Scholar 

  10. Xi HB, Wang GX, Fu B, Liu WP, Li Y . Survivin and PSMA Loaded Dendritic Cell Vaccine for the Treatment of Prostate Cancer. Biol Pharm Bull 2015; 38: 827–835.

    Article  CAS  Google Scholar 

  11. Kadowaki N . Dendritic cells: a conductor of T cell differentiation. Allergol Int 2007; 56: 193–199.

    Article  CAS  Google Scholar 

  12. Manicassamy S, Pulendran B . Dendritic cell control of tolerogenic responses. Immunol Rev 2011; 241: 206–227.

    Article  CAS  Google Scholar 

  13. Sakai K, Shimodaira S, Maejima S, Udagawa N, Sano K, Higuchi Y et al. Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma. J Neurosurg 2015; 123: 989–997.

    Article  CAS  Google Scholar 

  14. Anassi E, Ndefo UA . Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. P T 2011; 36: 197–202.

    PubMed  PubMed Central  Google Scholar 

  15. Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res 2014; 20: 2433–2444.

    Article  CAS  Google Scholar 

  16. DeLeo AB, Jay G, Appella E, Dubois GC, Law LW, Old LJ . Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A 1979; 76: 2420–2424.

    Article  CAS  Google Scholar 

  17. Levine AJ . p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323–331.

    Article  CAS  Google Scholar 

  18. Vogelstein B, Lane D, Levine AJ . Surfing the p53 network. Nature 2000; 408: 307–310.

    Article  CAS  Google Scholar 

  19. Gabrilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP . Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol 1996; 170: 111–119.

    Article  CAS  Google Scholar 

  20. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med. 1996; 183: 87–97.

    Article  CAS  Google Scholar 

  21. Noguchi Y, Chen YT, Old LJ . A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc Natl Acad Sci U S A. 1994; 91: 3171–3175.

    Article  CAS  Google Scholar 

  22. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA . Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A 1995; 92: 11993–11997.

    Article  CAS  Google Scholar 

  23. Röpke M, Hald J, Guldberg P, Zeuthen J, Nørgaard L, Fugger L et al. Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Natl Acad Sci U S A 1996; 93: 14704–14707.

    Article  Google Scholar 

  24. Nijman HW, Van der Burg SH, Vierboom MP, Houbiers JG, Kast WM, Melief CJ . p53, a potential target for tumor-directed T cells. Immunol Lett 1994; 40: 171–178.

    Article  CAS  Google Scholar 

  25. Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet JG, Choppin J . Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol 1998; 160: 328–333.

    CAS  PubMed  Google Scholar 

  26. Papadopoulos KP, Hesdorffer CS, Suciu-Foca N, Hibshoosh H, Harris PE . Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells. Clin Cancer Res 1999; 5: 2089–2093.

    CAS  PubMed  Google Scholar 

  27. Chikamatsu K, Nakano K, Storkus WJ, Appella E, Lotze MT, Whiteside TL et al. Generation of anti-p53 cytotoxic T lymphocytes from human peripheral blood using autologous dendritic cells. Clin Cancer Res 1999; 5: 1281–1288.

    CAS  PubMed  Google Scholar 

  28. Nikitina EY, Clark JI, Van Beynen J, Chada S, Virmani AK, Carbone DP et al. Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res 2001; 7: 127–135.

    CAS  PubMed  Google Scholar 

  29. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991; 51: 2979–2984.

    CAS  PubMed  Google Scholar 

  30. Tolcher AW, Hao D, de Bono J, Miller A, Patnaik A, Hammond LA et al. Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. J Clin Oncol 2006; 24: 2052–2058.

    Article  CAS  Google Scholar 

  31. Kanegae Y, Makimura M, Saito I . A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol 1994; 47: 157–166.

    Article  CAS  Google Scholar 

  32. Osugi Y, Vuckovic S, Hart DN . Myeloid blood CD11c(+) dendritic cells and monocyte-derived dendritic cells differ in their ability to stimulate T lymphocytes. Blood 2002; 100: 2858–2866.

    Article  CAS  Google Scholar 

  33. Russell PJ, Kingsley EA . Human prostate cancer cell lines. Methods Mol Med 2003; 81: 21–39.

    CAS  PubMed  Google Scholar 

  34. Yaginuma Y, Westphal H . Analysis of the p53 gene in human uterine carcinoma cell lines. Cancer Res 1991; 51: 6506–6509.

    CAS  PubMed  Google Scholar 

  35. Sasaki R, Shirakawa T, Zhang ZJ, Tamekane A, Matsumoto A, Sugimura K et al. Additional gene therapy with Ad5CMV-p53 enhanced the efficacy of radiotherapy in human prostate cancer cells. Int J Radiat Oncol Biol Phys 2001; 51: 1336–1345.

    Article  CAS  Google Scholar 

  36. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411–422.

    Article  CAS  Google Scholar 

  37. Liu Y, Kulesz-Martin M . P53 regulation and function in normal cells and tumors. Medicina (B Aires) 2000; 60: 9–11.

    CAS  Google Scholar 

  38. Ashcroft M, Vousden KH . Regulation of p53 stability. Oncogene 1999; 18: 7637–7643.

    Article  CAS  Google Scholar 

  39. Eastham JA, Stapleton AM, Gousse AE, Timme TL, Yang G, Slawin KM et al. Association of p53 mutations with metastatic prostate cancer. Clin Cancer Res 1995; 1: 1111–1118.

    CAS  PubMed  Google Scholar 

  40. Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, McCubrey JA . p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3. Cell Cycle 2012; 11: 4579–4588.

    Article  CAS  Google Scholar 

  41. Pisters LL, Pettaway CA, Troncoso P, McDonnell TJ, Stephens LC, Wood CG et al. Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancer. Clin Cancer Res 2004; 10: 2587–2593.

    Article  CAS  Google Scholar 

  42. Svane IM, Pedersen AE, Johansen JS, Johnsen HE, Nielsen D, Kamby C et al. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother 2007; 56: 1485–1499.

    Article  CAS  Google Scholar 

  43. Chiappori AA, Soliman H, Janssen WE, Antonia SJ, Gabrilovich DI . INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther 2010; 10: 983–991.

    Article  CAS  Google Scholar 

  44. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006; 12: 878–887.

    Article  CAS  Google Scholar 

  45. Thomas DJ, Robinson M, King P, Hasan T, Charlton R, Martin J et al. p53 expression and clinical outcome in prostate cancer. Br J Urol 1993; 72: 778–781.

    Article  CAS  Google Scholar 

  46. Shirakawa T, Gotoh A, Gardner TA, Kao C, Zhang ZJ, Matsubara S et al. p53 adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model. J Gene Med 2000; 2: 426–432.

    Article  CAS  Google Scholar 

  47. Shayakhmetov D.M, Gaggar A, Ni S, Li ZY, Lieber A . Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 2005; 79: 7478–7491.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was partially supported by the Japan Society for the Promotion of Science (JSPS) KAKENHI Grant Number 26461503.The materials including rAd-p53, rAd-LacZ, p53-DCs, and LacZ-DCs, were constructed only for this study, and were not commercially available.

Author information

Authors and Affiliations

  1. Division of Translational Research for Biologics, Department of Internal Related Medicine, Kobe University Graduate School of Medicine, Kobe, Japan

    H Saito, K Kitagawa & T Shirakawa

  2. Division of Advanced Medical Science, Kobe University Graduate School of Science, Technology and Innovation, Kobe, Japan

    T Yoneda, Y Fukui & T Shirakawa

  3. Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, Kobe, Japan

    M Fujsawa & T Shirakawa

  4. Modecs PI Inc, Quezon City, Philippines

    D Bautista

Authors
  1. H Saito
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Kitagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. T Yoneda
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Fukui
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Fujsawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Bautista
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T Shirakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Shirakawa.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Saito, H., Kitagawa, K., Yoneda, T. et al. Combination of p53-DC vaccine and rAd-p53 gene therapy induced CTLs cytotoxic against p53-deleted human prostate cancer cells in vitro. Cancer Gene Ther 24, 289–296 (2017). https://doi.org/10.1038/cgt.2017.21

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2017.21

This article is cited by

Search

Advanced search

Quick links